Quality improvement and practice-based research in neurology using the electronic medical record

Demetrius M. Maraganore, MD
Roberta Frigerio, MD
Nazia Kazmi, MS
Steven L. Meyers, MD
Meredith Sefa, MS
Shaun A. Walters, MS
Jonathan C. Silverstein, MD, MS

Abstract
We describe quality improvement and practice-based research using the electronic medical record (EMR) in a community health system-based department of neurology. Our care transformation initiative targets 10 neurologic disorders (brain tumors, epilepsy, migraine, memory disorders, mild traumatic brain injury, multiple sclerosis, neuropathy, Parkinson disease, restless legs syndrome, and stroke) and brain health (risk assessments and interventions to prevent Alzheimer disease and related disorders in targeted populations). Our informatics methods include building and implementing structured clinical documentation support tools in the EMR; electronic data capture; enrollment, data quality, and descriptive reports; quality improvement projects; clinical decision support tools; subgroup-based adaptive assignments and pragmatic trials; and DNA biobanking. We are sharing EMR tools and deidentified data with other departments toward the creation of a Neurology Practice-Based Research Network. We discuss practical points to assist other clinical practices to make quality improvements and practice-based research in neurology using the EMR a reality. Neuro Clin Pract 2015;5:419–429
The American Academy of Neurology (AAN) has proposed quality measures, but they have not been incorporated into electronic medical records (EMRs) by vendors.1–5 Quality measures documented as unstructured text are not captured discretely, making it difficult to report performance. Neurology is also hampered by a lack of comparative effectiveness research. There are several approved treatments for common neurologic disorders, but it is unknown which are superior in efficacy and tolerability and for which patient subgroups. Traditional clinical trials enroll selected patients, use surrogate measures, follow patients for short periods, and generalize poorly to clinical practice.6–9 Data captured in the EMR could be used to identify eligible patients, assign treatments, and measure outcomes at the point of care.10

To address these unmet needs, we created a quality improvement and practice-based research initiative in neurology using the EMR. We present a step-by-step description of our quality journey for 10 neurologic disorders (brain tumors, epilepsy, migraine, memory disorders, mild traumatic brain injury [mTBI], multiple sclerosis [MS], neuropathy, Parkinson disease [PD], restless legs syndrome, and stroke) and for brain health (risk assessments and interventions to prevent Alzheimer disease [AD] in targeted populations).

**Overview: A quality journey**

The Department of Neurology at NorthShore University HealthSystem (NorthShore) includes 40 neurologists practicing at 4 hospitals and 8 outpatient sites in the north suburbs of Chicago, IL. The neurologists include generalists and subspecialists in epilepsy, neurodegenerative disorders, MS, neuromuscular disorders, neuro-oncology, sleep disorders, and stroke. Figure 1 illustrates our stepwise process of quality improvement and practice-based research using the EMR. Figure 2 illustrates our progress for 11 projects (10 neurologic disorders plus brain health) as of April 1, 2015.

**Step 1: Structured clinical documentation support**

We optimized our EMR (Epic Systems Corporation) by building structured clinical documentation support (SCDS) toolkits that standardize office visits, write progress notes, and capture data. The process of creating the 11 SCDS toolkits (1 per project) is as follows.

**Content building** We conducted meetings with the neurologists in each program every 2 weeks to select a disorder that is prevalent, variable, and unpredictable and to standardize the content of progress notes (to define the disorder, specify its outcomes using validated measures, and document associated factors). We consulted the medical literature, AAN guidelines,11 National Institute of Neurological Diseases and Stroke Common Data Elements,12 and subspecialty guidelines.13 We envisioned standard workflows (the order and assignment of tasks to a care team that included a medical assistant, sometimes a nurse, and a neurologist) and progress notes (the order and layout in which the content would write). We limited the medical assistant and/or nurse assessments to 15 minutes each and the neurologist assessment to 60 minutes. Content building required 3 months per project.

**EMR building** We then conducted meetings with programmers from NorthShore’s EMR Optimization team every 2 weeks. They built SCDS toolkits that included navigators (a sidebar list of activities assigned to a workflow, with links to electronic forms), electronic forms (modules that included discrete data fields with mouse-click selection of variables represented by radio buttons, tabs, or drop-down menus and additional branching logic, autoscoring, and auto-interpretation features), and summary flow sheets (of prior test results or office visit information). We included optional free text fields (for typing additional comments or narrative history or the impression and plan). The toolkits were designed to support initial and long follow-up visits (conducted annually per our Best Practices, except for malignant brain tumors [every 6 months] and mTBI [at 2 weeks and 3 months]). The toolkits were also designed for optional use at interval visits (e.g., for medication adjustments or review of test results).
The SCDS toolkits were designed to support clinical practice and research. For example, an electronic pop-up box was built to prompt neurologists to enroll eligible patients in a DNA biobanking initiative. When the neurologist selected enrollment within the pop-up box, an electronic notice was sent to the research team to prompt consenting and blood drawing at the point of care or to document nonparticipation (and why). EMR building required 3 months per project.

**Implementation** The neurologists tested the SCDS toolkits in the EMR’s development environment. Revisions were made and the toolkits were moved to the EMR’s production environment. The project team continued to meet every 2 weeks to make revisions based on patient encounters. Implementation required 3 months per project.

In total, SCDS toolkit development required 9 months per project, and we worked on 3 toolkits a year (one undergoing content building, another EMR building, and another implementation at any time). Our toolkits focused on outpatient visits using the EMR’s ambulatory environment (except for brain tumors, which used the EMR’s hospital outpatient visit environment). As of April 1, 2015, 8 SCDS toolkits have been used several thousand times at routine office visits. Appendix e-1 at Neurology.org/cp provides screenshots of our toolkit for PD.
Step 2: Enrollment reports
After each SCDS toolkit implementation, neurologists met every 2 weeks with programmers specialized in extracting, transforming, and loading data from the EMR’s relational data repository to project-specific data marts in NorthShore’s Enterprise Data Warehouse (EDW). The data marts provide an interface for analytic tools. Up to 1,000 fields of data were captured per office visit. Neurologists provided input as to which tasks were required at initial and long follow-up visits and data were binned accordingly.

Within 1 month of project implementation, the EDW programmers created reports to track research enrollment in our DNA biobanking initiative. The enrollment reports are generated monthly. Tables indicate the number of participants by ethnicity and race or by month and year; the number of initial or follow-up visits per year; a listing of enrollees (including dates of consent and initial and follow-up visits, and annotations regarding death, withdrawal from the study, invalid consent, screen failure, or pending blood draw); and a summary of longitudinal follow-up (including numbers of patients actively followed, past due, pending due, or not due; and follow-up rates). Once enrollment reports were produced, project team meetings transitioned to monthly intervals.

Step 3: Data quality reports
After project-specific data marts were created and enrollment reports were available, the EDW programmers created data quality reports (as early as 3 months after an SCDS toolkit was implemented). These reports indicated which of the required data were missing for each office visit. Data quality reports are distributed to the care team monthly. Data not cleaned within 3 months were archived as permanently missing, and those data were not listed on subsequent reports. The care team learned where they were error prone from the data quality reports, and they remediated their use of the toolkits. When systematic errors occurred for many providers, the teams had the opportunity to improve their use of the toolkits or to request optimizations or a change in data requirements. The monthly reports produced only a few or no data checks per provider once projects were established.

Step 4: Descriptive reports (cohorts)
Once we enrolled 100 patients into a project and cleaned the data, a statistician created a descriptive report of the cohort. These reports include frequencies, medians, and ranges and bar
We empowered our neurologists to design the toolkits, reports, quality improvement projects, and best practice advisories to mitigate “physician burnout.”

and box plots for multiple fields of data and score tests (in the sample overall and in strata). These reports are generated quarterly, and by reviewing descriptive data at the cohort level, neurologists identify opportunities for quality improvement. Appendix e-2 provides a sample descriptive cohort report for migraine.

**Step 5: Quality improvement projects and dashboards**

Each neurology team envisioned 3 quality improvement projects using the SCDS toolkits, data, and reports. They developed projects using experience, medical literature searches, and additional Web site resources. Some quality improvement projects and measures were crosscutting but others were disorder-specific. Table 1 provides a list of quality improvement projects, disorders, and measures. We are analyzing baseline data for the first 100 patients enrolled per disorder and for the first year of follow-up to define quality benchmarks. The neurologists will review quality improvement “dashboards” quarterly.

**Next steps**

**Clinical decision support** We expect to improve quality by standardizing office visits using SCDS toolkits and by regularly reviewing enrollment, data quality, descriptive cohort, and quality improvement dashboard reports. As an added safeguard we are creating electronic pop-up boxes (best practice advisories [BPAs]) that fire at the point of care whenever a quality improvement opportunity is identified, based on data captured by the EMR.

For example, if a patient has PD and the neurologist documents recent falls or a positive pull test and the patient has not seen physical therapy in the past year, upon accepting the note, a BPA will fire and present the mouse-click options “order physical therapy” (which will place the order) or “defer physical therapy” (which will cascade and prompt selection of a reason for deferral). After implementing the BPA, we will track improvements in referral and fall rates vs benchmark data. We empowered our neurologists to design the toolkits, reports, quality improvement projects, and BPAs to mitigate “physician burnout.”

**Subgroup-based adaptive assignments** Neurologists will conduct pragmatic trials using the EMR for 10 common neurologic disorders. Table 2 lists the disorders, compared treatments, and outcomes. Our captured data will trigger BPAs prompting reassignment when a “to be compared” treatment is prescribed. For example, a neurologist might prescribe pramipexole to a patient with PD but be prompted to consider ropinirole or rotigotine instead. We will integrate with the EMR subgroup-based adaptive design (SUBA) software that uses data captured from the patients previously enrolled in a given trial to identify subgroup effects and to assign patients newly enrolled in the trial to treatments that are expected to be more effective in real time. The statistical features of SUBA include the continuous learning of patient subgroups based on a random partition model and the adaptive allocation of patients to the best treatment based on posterior predictive probabilities. SUBA has desirable performance in computer-simulated trials with a sample size of 300.

**Neurology practice-based research network** We created a neurology practice-based research network (NPBRN) using the EMR. We are sharing SCDS toolkits and data for quality
improvement and practice-based research. We obtained a list of Epic clients and invited neurology practices to join the NPBRN. The AAN is providing guidance regarding integration of quality measures into the EMR and assisting with recruitment of sites and dissemination of findings. Details are as follows (see also appendix e-4).

A. Sharing of SCDS toolkits. NorthShore is sharing its toolkits for 10 neurologic disorders with the other neurologists under a free license sharing agreement. Sharing of tools will be achieved via the EMR’s application exchange. This will substantially reduce the work of installing toolkits from one health system to another.

Table 1 Examples of quality improvement projects using the electronic medical record

<table>
<thead>
<tr>
<th>Quality initiatives</th>
<th>Disorders</th>
<th>Quality measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detect and manage psychosocial stress</td>
<td>Brain tumors, epilepsy</td>
<td>If NCCN or QOLIE-10 score positive, frequency of social worker referral order</td>
</tr>
<tr>
<td>Detect and manage depression or anxiety</td>
<td>Brain tumors, epilepsy, migraine, MCI, mTBI, MS, neuropathy, PD, RLS</td>
<td>If CES-D, GAD-7, GDS, or NDDI-E score positive, frequency of antidepressant or anxiolytic medication order and/or psychiatry referral order</td>
</tr>
<tr>
<td>Detect and manage cognitive impairment</td>
<td>Brain tumors, epilepsy, MCI, MS, PD, stroke</td>
<td>If MoCA test score positive, frequency of neuropsychological testing order or documentation of advance care planning</td>
</tr>
<tr>
<td>Prevent fall-related injury</td>
<td>Brain tumors, MCI, MS, neuropathy, PD, stroke</td>
<td>If falls in the past year or Hoehn and Yahr stage 3+ (PD), frequency of physical therapy order</td>
</tr>
<tr>
<td>Detect and manage osteoporosis</td>
<td>Brain tumors, epilepsy</td>
<td>If on enzyme-inducing anticonvulsant, frequency of bone density test order</td>
</tr>
<tr>
<td>Prevent teratogenesis</td>
<td>Brain tumors, epilepsy</td>
<td>If woman of childbearing age on anticonvulsant, frequency of folate medication order</td>
</tr>
<tr>
<td>Detect and manage sleep disorder</td>
<td>Epilepsy, migraine, mTBI, PD, RLS</td>
<td>If ESS or ISI screen positive, frequency of sleep study order</td>
</tr>
<tr>
<td>Detect temporal arteritis</td>
<td>Migraine</td>
<td>If age &gt; 55 y and headache less than 1 y, frequency of ESR and/or CRP order</td>
</tr>
<tr>
<td>Protect vulnerable adults</td>
<td>MCI</td>
<td>If FAQ reveals difficulty with financial management, frequency of social worker order</td>
</tr>
<tr>
<td>Prevent motor vehicle accidents</td>
<td>MCI, neuropathy, PD</td>
<td>If driving safety screen positive, frequency of driving evaluation order</td>
</tr>
<tr>
<td>Prevent complications of immunotherapy</td>
<td>MS, neuropathy</td>
<td>If steroids or disease-modifying therapies are prescribed, frequency of orders (CBC, CMP, TSH, pregnancy test, VZV antibody, JCV index, urinalysis, EKG, ophthalmology)</td>
</tr>
<tr>
<td>Detect Wilson disease</td>
<td>PD</td>
<td>If symptom onset &lt; age 55 y, frequency of ceruloplasmin order</td>
</tr>
<tr>
<td>Detect and manage compulsive disorder</td>
<td>PD, RLS</td>
<td>If compulsive disorder screens positive, frequency of discontinuation of dopamine agonist orders</td>
</tr>
<tr>
<td>Detect iron deficiency</td>
<td>RLS</td>
<td>If no ferritin or anemia testing in past year, frequency of iron, total iron binding capacity, ferritin, CBC order</td>
</tr>
</tbody>
</table>

Abbreviations: CBC = complete blood count; CES-D = Center for Epidemiologic Studies Depression; CMP = comprehensive metabolic panel; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; ESS = Epworth Sleepiness Scale; FAQ = Functional Activities Questionnaire; GAD-7 = Generalized Anxiety Disorder 7-item; GDS = Geriatric Depression Scale; ISID = Insomnia Severity Index; JCV = John Cunningham virus; MCI = mild cognitive impairment; MoCA = Montreal Cognitive Assessment; MS = multiple sclerosis; mTBI = mild traumatic brain injury; NCCN = National Comprehensive Cancer Network Distress Thermometer; NDDI-E = Neurological Disorders Depression Inventory for Epilepsy; PD = Parkinson disease; QOLIE-10 = Quality of Life in Epilepsy-10; RLS = restless legs syndrome; TSH = thyroid-stimulating hormone; VZV = varicella-zoster virus.

See appendix e-3 for e-references.
B. Sharing of deidentified data. The neurologists will share deidentified data captured by the SCDS toolkits (minus protected health information). The NPBRN will govern the use of the shared data collaboratively. We expect no overlapping patients (1 site per state).

C. Data management. NorthShore will manage the data in collaboration with other NPBRN sites. Data submitted to the EDW will be the object of constant monitoring. We will provide monthly encounter (akin to enrollment) reports and data quality reports, and quarterly descriptive cohort and quality improvement dashboard reports to participating neurologists.

### Table 2  Examples of pragmatic trials using the electronic medical record

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Compared treatments</th>
<th>Outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brain tumors</strong></td>
<td>Lamotrigine, levetiracetam, valproic acid</td>
<td>Survival (free of discontinuation, adjunctive therapy, seizures, hospice, death); 50% reduction of seizure frequency; Δ CES-D, GAD-7, KPS, MDASI, MoCA, NCCN</td>
</tr>
<tr>
<td><strong>Epilepsy (other seizures)</strong></td>
<td>Lamotrigine, levetiracetam, valproic acid</td>
<td>Survival (free of discontinuation, adjunctive therapy, seizures, death); 50% reduction of seizure frequency; Δ ESS, GAD-7, MoCA, NDDI-E, QOLIE-10</td>
</tr>
<tr>
<td><strong>MCI</strong></td>
<td>Donepezil (hs), rivastigmine patch, Namenda XR</td>
<td>Survival (free of discontinuation, adjunctive therapy, demential); Δ FAQ, GDS, MoCA</td>
</tr>
<tr>
<td><strong>Migraine (prophylaxis)</strong></td>
<td>Amitriptyline (hs), propranolol LA, topiramate (bid)</td>
<td>Survival (free of discontinuation, adjunctive therapy, medication overuse, chronic transformation); 50% reduction of migraine frequency; Δ CES-D, GAD-7, ISI, MIDAS, MSQ</td>
</tr>
<tr>
<td><strong>Migraine (abortive)</strong></td>
<td>Sumatriptan 100 mg (po), rizatriptan 10 mg (po), zolmitrptan 5 mg (po)</td>
<td>Survival (free of discontinuation, adjunctive therapy, medication overuse, chronic transformation); 2 hours pain relief; 2 hours and 24 hours pain free; Δ CES-D, GAD-7, ISI, MIDAS, MSQ</td>
</tr>
<tr>
<td><strong>mTBI</strong></td>
<td>Omega-3 fatty acids, education only</td>
<td>Survival (free of discontinuation, adjunctive therapy); RPCQ/Symptom Inventory (2 wk, 3 mo); Δ CES-D, GAD-7, ISI (3 mo)</td>
</tr>
<tr>
<td><strong>MS</strong></td>
<td>Acthar (SQ), methylprednisolone (IV), crossover (relapses)</td>
<td>Survival (free of discontinuation, adjunctive therapy, relapse, disease progression); Δ 9-hole peg, 25-ft walk, CES-D, EDSS, FSS, GAD-7, MoCA</td>
</tr>
<tr>
<td><strong>Neuropathy (painful)</strong></td>
<td>Duloxetine (am), pregabalin (bid), amitryptiline (hs)</td>
<td>Survival (free of discontinuation, adjunctive therapy); Δ CES-D, EQ-5D, Neuropathic Pain Scale</td>
</tr>
<tr>
<td><strong>PD</strong></td>
<td>Pramipexole ER, ropinirole XL, rotigotine patch</td>
<td>Survival (free of discontinuation, adjunctive therapy, levodopa, dyskinesias, motor fluctuations, freezing, falls, nursing home, death); Δ 9-hole peg, ESS, GDS, MoCA, UPDRS 1-6</td>
</tr>
<tr>
<td><strong>RLS</strong></td>
<td>Pramipexole (hs), ropinirole (hs), rotigotine patch</td>
<td>Survival (free of discontinuation, adjunctive therapy, augmentation, impulse control); Δ CES-D, ESS, GAD-7, IRLSSG, ISI, PSQI</td>
</tr>
<tr>
<td><strong>Stroke</strong></td>
<td>Aspirin, clopidogrel, clopidogrel (CYP2C19)</td>
<td>Survival (free of discontinuation, adjunctive therapy, TIA, ischemic stroke, intracranial hemorrhage, systemic hemorrhage, myocardial infarction, cancer, nursing home, death); Δ Barthel index, MoCA, mRankin, NIHSS</td>
</tr>
</tbody>
</table>

Abbreviations: CES-D = Center for Epidemiologic Studies Depression; EDSS = Expanded Disability Status Scale; EQ-5D = EuroQol 5-D; ESS = Epworth Sleepiness Scale; FAQ = Functional Activities Questionnaire; FSS = Functional Symptom Score; GAD-7 = Generalized Anxiety Disorder 7-item; GDS = Geriatric Depression Scale; IRLSSG = International Restless Legs Syndrome Study Group Severity Scale; ISI = Insomnia Severity Index; KPS = Karnofsky Performance Scale; MCI = mild cognitive impairment; MDASI = MD Anderson Symptom Inventory; MIDAS = Migraine Disability Assessment; MoCA = Montreal Cognitive Assessment; mRankin = modified Rankin Scale; MS = multiple sclerosis; MSQ = Migraine-Specific Quality-of-Life Questionnaire; mTBI = mild traumatic brain injury; NCCN = National Comprehensive Cancer Network Distress Thermometer; NDDI-E = Neurological Disorders Depression Inventory for Epilepsy; NIHSS = NIH Stroke Scale; PD = Parkinson disease; PSQI = Pittsburgh Sleep Quality Index; QOLIE-10 = Quality of Life in Epilepsy-10; RLS = restless legs syndrome; RPCQ = Rivermead Post-Concussion Symptoms Questionnaire; UPDRS = Unified Parkinson’s Disease Rating Scale.

See appendix e-3 for e-references.
Analyses of the data. For each quality improvement initiative (table 1), we will describe the baseline demographic and clinical characteristics for the patients by site and combined. Several statistical packages interface with the EDW and will be used for comparisons. Neurologists are expected to assess thousands of unique patients per year at each NPBRN site separately and tens of thousands of new and established patients per year combined. We have registered the NPBRN (8 sites presently).25

**Biobanking and research informatics initiative** A driver of our quality journey at North-Shore has been our department’s biobanking and research informatics initiative. Neurologists are enrolling 1,000 patients in each of 11 SCDS cohorts. Following informed consent and with institutional review board approval, enrollees provide a blood sample for DNA and plasma storage and permission to associate information in their blood with information in their medical records. We will use this resource for molecular prognostic studies. Appendix e-5 summarizes biobanking as of April 1, 2015.

**Practical points**

From the point of view of practicing neurologists, our use of the EMR may seem futuristic. Many neurologists do not use an EMR or have limited capabilities for its optimization or data sharing. Nevertheless, we conclude by addressing many practical points to assist other clinical practices in making quality improvements and practice-based research using the EMR a reality.

**How to promote buy-in** Physicians and staff may resist the implementation of SCDS toolkits and related clinical workflows. To build buy-in we regularly communicated benefits of SCDS, including (1) care navigation, (2) note writing, (3) timely communications, (4) value-based payment, (5) patient safety, (6) quality improvement, (7) comparative effectiveness, (8) personalized medicine, (9) scholarly activities, and (10) innovation. We engaged the neurologists in the design, building, and implementation of toolkits and the related reports and quality improvement initiatives and met regularly to improve tools and processes. We incorporated bonuses for group performance in quality goals into our compensation model. In other practices the data captured might also be used to meet federal quality reporting mandates such as the Physician Quality Reporting System.26,27

Our objective was to stay “time neutral.” We encouraged neurologists to pilot test the SCDS toolkits in the EMR development environment and we placed frequent requests for optimizations post implementation. Our new office visits and long follow-up visits are 60 minutes each (neurologist component) and we support our neurologists with medical assistants or sometimes nurses, but the time and resources allocated can easily be reduced because of the modular build of our toolkits. Other neurology practices may choose to designate some toolkits (navigators) or modules (electronic forms) as required and others as optional or to implement neurology office visit workflows including students, residents, fellows, physician assistants, or advanced practice nurses (in addition to or instead of medical assistants and nurses).

We also anticipate challenges to the conduct of practice-based research, such as pragmatic trials, using the EMR.28 Neurologists or patients may find it cumbersome to engage in research at the point of care. Ethicists determined that pragmatic trials comparing standard therapies via the EMR with no additional burden or risk to patients might be exempted from informed consent.29 Alternatively, the burden of informed consent can be reduced by using electronic consent forms. Consenting electronically at the point of care is standard practice for risk-bearing clinical procedures at some institutions, and others have reported a favorable experience with electronic consenting for research.30,31

**How to promote collaboration** We are licensing the use of our SCDS toolkits to other neurology practices at no direct cost, provided they are willing to join the NPBRN and share de-identified data. The installation costs for the toolkits will be nominal compared with the installation costs of the EMR (and a fraction of the cost of building toolkits from scratch). Practices that use EMRs are accustomed to some annual cost associated with upgrades. All of the
NPBRN principal investigators are department leaders, and we will regularly discuss engagement tactics. We will accommodate shorter office visits at some sites by designating a minimal set of SCDS toolkits or modules as required and others as recommended. We are exploring workflows in which patients may self-enter some information into the electronic forms using an online portal or computer kiosks or tablet computers at check-in to accommodate clinical practices with limited staff support. We will empower neurologists at each NPBRN site to propose changes to the toolkits and to have access to data. We will provide reports at the patient encounter (rather than research enrollment) level. NorthShore will leverage its experience in the conduct of EMR-based data sharing in a consortium.32

We also hope that EMR vendors will incorporate SCDS toolkits similar to ours and make them broadly available to clients as part of their standard products. Once common data elements are extracted, transformed, and loaded into a data warehouse (regardless of the EMR platform), the same enrollment/encounter, descriptive, and quality reports can be used and the quality improvement initiatives can be the same. The AAN is creating a registry (the Axon Registry) to demonstrate the quality and value of neurologic care, to support improvements to care, and to alleviate the administrative burdens of quality reporting for payment and maintenance of certification.33 Data captured using SCDS toolkits such as ours can be easily exported to the AAN registry, forgoing the need for extraction software, natural language processing, or chart abstraction.

REFERENCES


ACKNOWLEDGMENT
The authors acknowledge the generous funding support of the Auxiliary of NorthShore University HealthSystem and thank the medical assistants, nurses, neurologists, EMR Optimization and Enterprise Data Warehouse programmers, administrators, and research personnel at NorthShore University HealthSystem who contributed to the quality improvement and practice-based research initiative using the EMR. The authors thank Vimal Patel, PhD for his assistance with editing, formatting, and submitting the manuscript for publication. We also thank the principal investigators of the neurology practice-based research network and Becky Schierman, MPH and Dr. Timothy Pedley of the American Academy of Neurology for their collaboration. Finally, the authors thank the neurology patients who inspire us to improve quality and to innovate our clinical practice.

AUTHOR CONTRIBUTIONS
Demetrius M. Maraganore: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, acquisition of data, statistical analysis, study supervision, obtaining funding. Roberta Frigerio: drafting/revising the manuscript, analysis or interpretation of data, acquisition of data, study supervision. Nazia Kazmi: drafting/revising the manuscript, acquisition of data, study supervision. Steven L. Meyers: drafting/revising the manuscript, analysis or interpretation of data, acquisition of data, study supervision. Meredith Sefa: drafting/revising the manuscript. Shaun A. Walters: analysis or interpretation of data, acquisition of data, statistical analysis. Jonathan C. Silverstein: drafting/revising the manuscript, study concept or design, acquisition of data, study supervision.
STUDY FUNDING
Targeted study funding is provided by the Agency for Healthcare Research and Quality grant 1R01HS024057-01 “Quality Improvement and Practice Based Research in Neurology Using the EMR,” awarded to D.M.M. on June 30, 2015 (after this paper was accepted for publication).

DISCLOSURES
D.M. Maraganore has received philanthropic support from the Auxiliary of NorthShore University HealthSystem; serves on the editorial board of Parkinsonism and Related Disorders; is an author on 2 pending patents: (1) method to treat Parkinson’s disease and (2) method to predict Parkinson’s disease; and receives research support from GE Healthcare and the Agency for Health Care Research and Quality (1R01HS024057-01). R. Frigerio’s spouse has received philanthropic support from the Auxiliary of NorthShore University HealthSystem; serves on the editorial board of Parkinsonism and Related Disorders; is an author on 2 pending patents: (1) method to treat Parkinson’s disease and (2) method to predict Parkinson’s disease; and receives research support from GE Healthcare and the Agency for Health Care Research and Quality (1R01HS024057-01). N. Kazmi is employed as a Clinical Research Associate at Cepheid and serves as a consultant for Nutrabiots, LLC. S.L. Meyers and M. Sefa report no disclosures. S.A. Walters is employed as Senior Programmed/Analyst at NorthShore University Health System. J.C. Silverstein serves on a scientific advisory board for Western Governors University Health Professions Council; is cofounder of Computationdoc LLC; receives research support from Baxter, a Patient-Centered Outcomes Research Institute subgrant from Chicago Community Trust CDRN CAPiCORN, and a Centers for Medicare and Medicaid Services subgrant from University of Chicago; and is President and CEO of the Joseph H. Kanter Foundation, a 501c3 doing health care research (salary support to NorthShore as release time). Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Quality improvement and practice-based research in neurology using the electronic medical record
Demetrius M. Maraganore, Roberta Frigerio, Nazia Kazmi, et al.
*Neurol Clin Pract* 2015;5;419-429 Published Online before print September 24, 2015
DOI 10.1212/CPJ.0000000000000176

This information is current as of September 24, 2015

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://cp.neurology.org/content/5/5/419.full.html">http://cp.neurology.org/content/5/5/419.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://cp.neurology.org/content/suppl/2015/09/24/CPJ.000000000000000000000000000000DC1">http://cp.neurology.org/content/suppl/2015/09/24/CPJ.000000000000000000000000000000DC1</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 25 articles, 2 of which you can access for free at: <a href="http://cp.neurology.org/content/5/5/419.full.html##ref-list-1">http://cp.neurology.org/content/5/5/419.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Citations</td>
<td>This article has been cited by 4 HighWire-hosted articles: <a href="http://cp.neurology.org/content/5/5/419.full.html##otherarticles">http://cp.neurology.org/content/5/5/419.full.html##otherarticles</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://cp.neurology.org/misc/about.xhtml#permissions">http://cp.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://cp.neurology.org/misc/addir.xhtml#reprintsus">http://cp.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>

*Neurol Clin Pract* is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2015 American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.